ArticleFrontiers in physiology2026
Effects of Kuanxiong aerosol for preventing acute mountain sickness: an exploratory small-sample randomized, placebo-controlled trial.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the potential efficacy and neurophysiological effects of Kuanxiong Aerosol (KXA) in preventing acute mountain sickness (AMS) during simulated high-altitude exposure. Methods: In this randomized, double-blind, placebo-controlled trial, 20 healthy volunteers underwent a 6-hour hypobaric hypoxia session (simulated 4000 m) after receiving either KXA or placebo. Outcomes included the Lake Louise Score (LLS), AMS incidence, physiological parameters (SpO Results: In the main trial, KXA administration was associated with a non-significant reduction in total LLS and a decrease in AMS incidence from 50% (placebo) to 30% (KXA). No significant differences were observed in SpO Conclusion: KXA shows preliminary potential for alleviating AMS symptoms under simulated high-altitude conditions, possibly through cardiac and regional cerebrovascular modulation. These findings support further investigation in larger, randomized controlled trials in real-world high-altitude settings to confirm efficacy and clarify the underlying mechanisms. Chinese clinical trial registry: ChiCTR2500105469.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.